Adherence clubs linked to 30% reduction in high viral load among postpartum South African women living with HIV
Weight gain after starting HIV treatment may have genetic influences
New approaches for paediatric dosing: abacavir in newborns, doubling dolutegravir with rifampicin
New mothers with HIV gain more weight on dolutegravir than efavirenz
Yes, the same life expectancy as HIV-negative people, but far fewer years in good health
Taking PrEP during acute HIV infection for more than 2-3 weeks is likely to cause resistance, Thai study finds
Long-acting capsid inhibitor GS-6207 confirms safety and antiviral activity
HIV vaccine that generates broadly neutralising antibodies passes first safety and proof-of-concept study in humans
Dolutegravir-based HIV treatment is the safest and most effective choice for pregnant women
